Innova Biosciences introduces InnovaCoat GOLD-Carboxyl nanoparticles
Functionalized gold nanoparticles for easy, fast covalent conjugation of antibodies.
Innova Biosciences, a specialist provider of bioconjugation products and services, has launched a carboxylated derivative of its unique InnovaCoat GOLD 40 nm nanoparticles. The new product enables customers to quickly generate highly stable covalent gold-antibody conjugates at R&D and manufacturing scales.
The InnovaCoat GOLD-Carboxyl surface is optimized for single step EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) covalent coupling, without signs of aggregation, and eliminates the need for EDC/NHS (N-Hydroxysuccinimide) pre-activation and washing steps associated with traditional conjugations. The process is also significantly faster than standard methods, with conjugates ready to use in less than 35 minutes.
Anna Sereni, Team Leader of Particles at Innova Biosciences, commented: “The InnovaCoat GOLD-Carboxyl nanoparticles build upon Innova’s continuously expanding range of particle technologies, which also includes gold and latex conjugation kits, as well as pre-conjugated gold and colloidal gold. Innova’s broadening product range offers increased flexibility to those working within in-vitro diagnostics, as well as in other industries which utilize nanoparticle technologies.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance